<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">26960450</PMID><DateCompleted><Year>2017</Year><Month>01</Month><Day>16</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>31</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1434-9949</ISSN><JournalIssue CitedMedium="Internet"><Volume>35</Volume><Issue>4</Issue><PubDate><Year>2016</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Clinical rheumatology</Title><ISOAbbreviation>Clin Rheumatol</ISOAbbreviation></Journal><ArticleTitle>The investigation of killer cell immunoglobulin-like receptor genotyping in patients with systemic lupus erytematosus and systemic sclerosis.</ArticleTitle><Pagination><StartPage>919</StartPage><EndPage>925</EndPage><MedlinePgn>919-25</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s10067-016-3222-0</ELocationID><Abstract><AbstractText>Systemic lupus erythematosus (SLE) is an autoimmune disease characterised by the production of autoantibodies and the involvement of multiple organ systems. Systemic sclerosis (SSc) is another autoimmune disease that causes fibrosis. We will aim to analyse the role of killer cell immunoglobulin-like receptor (KIR) genotypes and their existence with the respective HLA ligands in patients with SLE and SSc. Forty-five SLE, 25 SSc and 40 healthy controls were included. We examined the presence/absence of KIR2DL1, 2DL2, 2DL3, 2DL4, 2DL5A, 2DL5B, 2DS1, 2DS1, 2DS2, 2DS3, 2DS4, 2DS5, 3DL1, 3DL2, 3DL3, 3DS1, 2DP1, 3DP1 and their known HLA ligands. In the SLE group, the KIR2DL5, KIR2DL5B and KIR2DS3 genes were significantly more frequent, and KIR2DL3 gene was significantly less than in controls (p values &lt;0.05). In SSc patients, the KIR2DS3 gene was more frequent than in controls (p&#x2009;=&#x2009;0.032). The KIR2DL3 gene was detected more frequently in controls while KIR2DS3 gene was more frequent in the patient group when SLE and SSc patients were combined (p values&#x2009;&lt;&#x2009;0.05). The KIR2DS2/HLA-C and KIR2DS2/HLA-C combinations were significantly more in both SLE and SSc groups than in controls. The KIR2DL2 and KIR2DL5B genes were protective from neurologic involvement in SLE patients (p values &lt;0.05). The variations of some KIR genes such as KIR2DL5, KIR2DL5B, KIR2DS3 and KIR2DL3 may have a role in the pathogenesis of SLE and SSc. Also, the presence of KIR2DL2 and KIR2DL5B may cause major organ involvement, like neurologic involvement, in SLE.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Tozk&#x131;r</LastName><ForeName>J&#xfc;lide Duymaz</ForeName><Initials>JD</Initials><AffiliationInfo><Affiliation>Health Services Vocational College, Trakya University, Edirne, Turkey. jduymaz@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tozk&#x131;r</LastName><ForeName>Hilmi</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Medical Faculty, Division of Medical Genetics, Trakya University, Edirne, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>G&#xfc;rkan</LastName><ForeName>Hakan</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Medical Faculty, Division of Medical Genetics, Trakya University, Edirne, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>D&#xf6;nmez</LastName><ForeName>Salim</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Medical Faculty, Division of Rheumatology, Trakya University, Edirne, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Eker</LastName><ForeName>Damla</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Medical Faculty, Division of Medical Genetics, Trakya University, Edirne, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pamuk</LastName><ForeName>G&#xfc;ls&#xfc;m Emel</ForeName><Initials>GE</Initials><AffiliationInfo><Affiliation>Medical Faculty, Division of Haematology, Trakya University, Edirne, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pamuk</LastName><ForeName>&#xd6;mer Nuri</ForeName><Initials>&#xd6;N</Initials><AffiliationInfo><Affiliation>Medical Faculty, Division of Rheumatology, Trakya University, Edirne, Turkey.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2016</Year><Month>03</Month><Day>09</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Clin Rheumatol</MedlineTA><NlmUniqueID>8211469</NlmUniqueID><ISSNLinking>0770-3198</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015236">HLA-C Antigens</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C515077">KIR2DL2 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C515078">KIR2DL3 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C515081">KIR2DL5B protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C541358">KIR2DS3 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008024">Ligands</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D054340">Receptors, KIR</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D054343">Receptors, KIR2DL2</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D054344">Receptors, KIR2DL3</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D054346">Receptors, KIR2DL5</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000483" MajorTopicYN="N">Alleles</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005787" MajorTopicYN="N">Gene Frequency</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005838" MajorTopicYN="Y">Genotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015236" MajorTopicYN="N">HLA-C Antigens</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006239" MajorTopicYN="N">Haplotypes</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008024" MajorTopicYN="N">Ligands</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="N">Lupus Erythematosus, Systemic</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D054340" MajorTopicYN="N">Receptors, KIR</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D054343" MajorTopicYN="N">Receptors, KIR2DL2</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D054344" MajorTopicYN="N">Receptors, KIR2DL3</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D054346" MajorTopicYN="N">Receptors, KIR2DL5</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012595" MajorTopicYN="N">Scleroderma, Systemic</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Genetic</Keyword><Keyword MajorTopicYN="N">Killer cell immunoglobulin-like receptors (KIRs)</Keyword><Keyword MajorTopicYN="N">Systemic lupus erythematosus (SLE)</Keyword><Keyword MajorTopicYN="N">Systemic sclerosis (SSc)</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2015</Year><Month>11</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>2</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2016</Year><Month>2</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>3</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>3</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>1</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26960450</ArticleId><ArticleId IdType="doi">10.1007/s10067-016-3222-0</ArticleId><ArticleId IdType="pii">10.1007/s10067-016-3222-0</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Blood. 2002 Dec 1;100(12):4098-107</Citation><ArticleIdList><ArticleId IdType="pubmed">12393468</ArticleId></ArticleIdList></Reference><Reference><Citation>Rheumatology (Oxford). 2013 Nov;52(11):1952-62</Citation><ArticleIdList><ArticleId IdType="pubmed">23804219</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Rev Immunol. 2005 Mar;5(3):201-14</Citation><ArticleIdList><ArticleId IdType="pubmed">15719024</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Rev Immunol. 2004 Mar;4(3):190-8</Citation><ArticleIdList><ArticleId IdType="pubmed">15039756</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Exp Immunol. 2010 Jun;160(3):325-30</Citation><ArticleIdList><ArticleId IdType="pubmed">20082621</ArticleId></ArticleIdList></Reference><Reference><Citation>Tissue Antigens. 2007 Apr;69 Suppl 1:106-8</Citation><ArticleIdList><ArticleId IdType="pubmed">17445179</ArticleId></ArticleIdList></Reference><Reference><Citation>Arthritis Rheum. 1980 May;23(5):581-90</Citation><ArticleIdList><ArticleId IdType="pubmed">7378088</ArticleId></ArticleIdList></Reference><Reference><Citation>Autoimmun Rev. 2015 Nov;14(11):1005-18</Citation><ArticleIdList><ArticleId IdType="pubmed">26164648</ArticleId></ArticleIdList></Reference><Reference><Citation>Arthritis Rheum. 2004 May;50(5):1561-5</Citation><ArticleIdList><ArticleId IdType="pubmed">15146426</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 2014 Feb 18;111(7):2662-7</Citation><ArticleIdList><ArticleId IdType="pubmed">24550293</ArticleId></ArticleIdList></Reference><Reference><Citation>Annu Rev Immunol. 2002;20:853-85</Citation><ArticleIdList><ArticleId IdType="pubmed">11861620</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 2008 Feb 26;105(8):3053-8</Citation><ArticleIdList><ArticleId IdType="pubmed">18287063</ArticleId></ArticleIdList></Reference><Reference><Citation>Lupus. 2008 Sep;17(9):793-8</Citation><ArticleIdList><ArticleId IdType="pubmed">18755860</ArticleId></ArticleIdList></Reference><Reference><Citation>J Exp Med. 2003 Apr 7;197(7):933-8</Citation><ArticleIdList><ArticleId IdType="pubmed">12668644</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Exp Immunol. 2015 May;180(2):250-4</Citation><ArticleIdList><ArticleId IdType="pubmed">25581336</ArticleId></ArticleIdList></Reference><Reference><Citation>Lupus. 2011 Mar;20(3):265-73</Citation><ArticleIdList><ArticleId IdType="pubmed">21233146</ArticleId></ArticleIdList></Reference><Reference><Citation>Annu Rev Immunol. 2002;20:217-51</Citation><ArticleIdList><ArticleId IdType="pubmed">11861603</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Exp Rheumatol. 2011 Mar-Apr;29(2 Suppl 65):S75-86</Citation><ArticleIdList><ArticleId IdType="pubmed">21586222</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>